Health Professional Radio - Podcast

Dr. Angelos Stergiou, President and CEO of SELLAS Life Sciences Group, a late-stage clinical biopharmaceutical company discusses their Phase 3 lead asset, Galinpepimut-S (GPS) a novel immunotherapy that helps to prolong overall survival for cancer patients who are in remission as a monotherapy.  He talks about the various indications that GPS targets and the company's focus on the Wilms Tumor 1 (WT1) antigen and why they are the most advanced company working on this in the space. Dr. Angelos M. Stergiou is the founder, President and Chief Executive Officer of SELLAS Life Sciences Group, Inc. Prior to founding SELLAS in 2012, Dr. Stergiou co-founded Genesis Life Sciences, Ltd. (now Genesis Research), a boutique health economics and pricing-reimbursement and health access company, where he served as President and Chief Operating Officer from 2009 to 2011. From 2002 to 2009, Dr. Stergiou held international positions of increasing responsibility in pharmaceutical and biotechnology companies, including PAION